Clinical Trial Search

Primary: Percentage of Participants With PSA50 Response — 2 Participants

Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions

Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…

Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants

Primary: Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA) — 1 Participants

Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants

Primary: PSA Response — 0 participants

Primary: Impact on Patient Treatment /Management — 66; 38; 53; 5 Participants

Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants

Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants

Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)

Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data

Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale

Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up

Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true

Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants

Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax

Primary: Biochemical Response Rate — 0 participants

Primary: The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. — 126; 87; 88; 34 Participants

Primary: Safety, Feasibility and Tolerance of Revlimid as Assessed by Number of Participants Experiencing Grade 3 and 4 Adverse Events. — 3; 10 Participants

Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020

Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months

Primary: Relapse-free Survival — 13; 10 months

Primary: Changes in 18F-fluciclovine PET Scan for Patients With mCRPC on Treatment With Life Prolonging Therapies — 5; 0; 3; 0 Participants

Primary: Time to Disease Progression — 15.2 weeks

Primary: Percent of Participants With Freedom of PSA (Prostate Specific Antigen) Progression — 84; 66 Percent of patients with no progession

Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants

Primary: Safety and Tolerability — 8; 8; 0; 0 Participants

Primary: Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels — 5 percentage of participants

Primary: Rate of Rise of Serum PSA — 0.0825 Nanograms Per Milliliter